Shandong Boan Biotechnology (HKG:6955) announced plans to buy back up to HK$200 million of its shares, according to a Wednesday filing with the Hong Kong bourse.
The pharmaceutical company's shares gained over 3% in morning trade Thursday.
Shandong Boan Biotechnology (HKG:6955) announced plans to buy back up to HK$200 million of its shares, according to a Wednesday filing with the Hong Kong bourse.
The pharmaceutical company's shares gained over 3% in morning trade Thursday.
Zhejiang FORE Intelligent Technology (SHE:301368) plans to raise up to 730 million yuan from share placement plan, according to a Shenzhen bourse filing on Thursday.The company plans to issue up to around 36 million shares to up to 35 investors.Proceeds from the placement will be used to fund the construction of a factory for precision power gears for new energy vehicles, a precision transmission manufacturing plant, and a precision transmission research and development center.The remaining proceeds of up to 200 million yuan will be used to supplement the company's working capital.The Chinese gear manufacturer's shares fell 2% during the midday trade.
Huadong Medicine's (SHE:000963) unit, Hangzhou Sino-American Huadong Pharmaceutical, received approval from China's National Medical Products Administration for the clinical trials of HDM2017 for injection, according to a Shenzhen bourse filing on Thursday.The drug is used in combination with Fruquintinib for the treatment of advanced colorectal cancer.
Chinese President Xi Jinping said Beijing and Washington's economic teams reached a "generally balanced and positive outcome" during Wednesday's meeting, Xinhua News Agency reported Thursday.Xi made the remarks after welcoming U.S. President Donald Trump in Beijing.U.S. Treasury Secretary Scott Bessent and Chinese Vice Premier He Lifeng met in South Korea on Wednesday, ahead of the high-stakes meeting on Thursday, the BBC reported."Facts have repeatedly proven that there are no winners in a trade war, and the essence of China-US economic and trade relations is mutual benefit and win-win cooperation," Xinhua quoted Xi as saying.